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Abstract
Background: Ets-1 controls osteoblast differentiation and bone development; however, its downstream mechanism of
action in osteoblasts remains largely undetermined. CCN2 acts as an anabolic growth factor to regulate osteoblast
differentiation and function. CCN2 is induced by TGF-b1 and acts as a mediator of TGF-b1 induced matrix production in
osteoblasts; however, the molecular mechanisms that control CCN2 induction are poorly understood. In this study, we
investigated the role of Ets-1 for CCN2 induction by TGF-b1 in primary osteoblasts.
Results: We demonstrated that Ets-1 is expressed and induced by TGF-b1 treatment in osteoblasts, and that Ets-1 over-
expression induces CCN2 protein expression and promoter activity at a level similar to TGF-b1 treatment alone. Additionally,
we found that simultaneous Ets-1 over-expression and TGF-b1 treatment synergize to enhance CCN2 induction, and that
CCN2 induction by TGF-b1 treatment was impaired using Ets-1 siRNA, demonstrating the requirement of Ets-1 for CCN2
induction by TGF-b1. Site-directed mutagenesis of eight putative Ets-1 motifs (EBE) in the CCN2 promoter demonstrated
that specific EBE sites are required for CCN2 induction, and that mutation of EBE sites in closer proximity to TRE or SBE (two
sites previously shown to regulate CCN2 induction by TGF-b1) had a greater effect on CCN2 induction, suggesting potential
synergetic interaction among these sites for CCN2 induction. In addition, mutation of EBE sites prevented protein complex
binding, and this protein complex formation was also inhibited by addition of Ets-1 antibody or Smad 3 antibody,
demonstrating that protein binding to EBE motifs as a result of TGF-b1 treatment require synergy between Ets-1 and Smad
3.
Conclusions: This study demonstrates that Ets-1 is an essential downstream signaling component for CCN2 induction by
TGF-b1 in osteoblasts, and that specific EBE sites in the CCN2 promoter are required for CCN2 promoter transactivation in
osteoblasts.
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Introduction
Osteoblast growth, differentiation, and biosynthetic activity are
initiated and tightly regulated by systemic and locally produced
growth factors. Recently, connective tissue growth factor (CCN2),
a 38 kDa, cysteine rich, extracellular matrix (ECM) protein that
belongs to the CCN family of proteins, has emerged as an
important growth factor in the control and regulation of
osteogenesis [1] [2,3,4,5]. CCN2 null (2/2) mice exhibit multiple
skeletal dysmorphisms as a result of impaired growth plate
chondrogenesis, angiogenesis, and bone formation/mineralization
[6], and also exhibit numerous defects in the craniofacial, axial,
and appendicular skeleton [7]. CCN2 is highly expressed in active
osteoblasts lining osteogenic surfaces and is produced and secreted
by osteoblasts in culture [2,8]. CCN2 promotes proliferation,
matrix production, and differentiation in osteoblasts
[2,5,9,10,11,12,13], and CCN2 levels are stimulated by trans-
forming growth factor-b1 (TGF-b1) [8,13,14], a finding that is
consistent with a role for CCN2 in the effects of these proteins on
skeletal growth [15]. TGF-b1 is a potent, multifunctional,
osteogenic growth factor that also regulates osteoblast differenti-
ation and function [16]. One of the major effects of TGF-b1o n
osteoblasts is its ability to stimulate the production and secretion of
ECM [17,18,19,20], however the mechanisms or downstream
effector genes that mediate this response are not understood. In
osteoblasts, we recently demonstrated that CCN2 is stimulated by
TGF-b1, and that CCN2 is a downstream effector for TGF-b1
induced ECM synthesis [8,13,14]. The signaling pathways that
mediate TGF-b1 induction of CCN2 vary depending on the cell
type being examined [21], and in osteoblasts they have only begun
to be characterized. We have recently demonstrated that CCN2
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of both the Smad and Erk signaling pathways [22,23].
In general, TGF-b1 signals through a generic Smad mediated
pathway involving Smads 2, 3, and 4 [24]. Smads 2 and 3 are
phosphorylated by active transmembrane serine/threonine TGF-
b1 receptors [25]. Following activation, Smad 2 and 3 form a
trimeric complex with Smad 4, and this complex subsequently
translocates to the nucleus, where it binds to Smad binding
elements (SBE) in promoters of TGF-b1-responsive genes [24,26].
Transcriptional activation by Smads is not limited to the Smad-
SBE interaction alone but requires additional association of Smads
with other transcription factors and co-factors that together bind
the SBE and adjacent cis-regulatory binding elements (DNA
motifs) [27]. We have previously demonstrated that in osteoblasts,
the TGFb response element (TRE/aka the BCE) in addition to the
SBE, is essential for CCN2 promoter activation by TGF-b1
[22,23]. However, the requisite additional transcription factors,
co-factors, and DNA motifs required for Smad transcriptional
activation are highly cell type dependent, and studies aimed at
identifying these factors/motifs in osteoblasts are in their infancy.
We recently demonstrated that the MAPK, Erk, is also required
for CCN2 induction by TGF-b1 in osteoblasts [22]. The
requirement of Smad and Erk signaling to achieve CCN2
induction has also been demonstrated in other cells types
[28,29,30,31,32,33,34]. Erk is known to potentiate the TGF-b1/
Smad pathway via direct phosphorylation of Smads or indirectly
through activation/inactivation of co-activators/co-repressors that
mediate Smad DNA binding [35,36]. We recently demonstrated
that activation (phosphorylation) of Smads is not dependent on
Erk, but that Erk phosphorylation is required for transcriptional
complex formation on the SBE [23]. These results suggest that Erk
mediates Smad signaling through activation of nuclear transcrip-
tion factors that enhance Smad DNA binding. Activated Erk can
translocate to the nucleus where it activates downstream
transcription factors [37]. Erythroblastosis virus E26 oncogene
homologue 1 (Ets-1) is a transcription factor that has been shown
to be directly phosphorylated by Erk, and this leads to its
activation and subsequent binding to Ets-1 binding motifs (EBE) in
the promoters of target genes [37,38,39,40].
Ets-1 is the founding member of the Ets family of transcription
factors that control a wide variety of important biological processes
including cell proliferation, differentiation, and ECM regulation
[41]. Ets-1 is a downstream signaling effector for several TGF-b1
responsive genes [42,43,44], and more recently, Ets-1 has been
shown to function downstream of TGF-b1 for CCN2 induction in
fibroblasts [45]. Transcriptional activation by Ets-1 proteins
functions in a combinatorial manner through association with
other transcription co-factors to transactivate target genes [46,47].
Recently, Ets-1 was found to synergize with Smad 3 to activate
CCN2 expression in fibroblasts [48], and in separate studies, it was
shown that Smad3 and Ets-1 co-immunoprecipitate and can act to
form transcriptionally active complexes with the Smad transcrip-
tional co-activators p300 and CBP [49,50]. Ets-1 regulates
transcription of target genes in a cell specific manner, and the
role of Ets-1 for CCN2 regulation by TGF-b1 in osteoblasts is
unknown. In this study, we investigated the contribution of Ets-1
for induction of CCN2 by TGF-b1 in osteoblasts.
Results
TGF-b1 induction of CCN2 requires Ets-1 in osteoblasts
Ets-1 is a downstream signaling effector for several TGF-b1
responsive genes [42,43,44], and more recently Ets-1 has been
shown to function downstream of TGF-b1 for CCN2 induction in
fibroblasts [45]. In this study, we examined whether Ets-1
expression could be induced by TGF-b1 treatment of osteoblasts.
The TGF-b1 dose of 5 ng/ml was used for this and all subsequent
experiments, since we had previously demonstrated that this was
the minimal dose required for maximal induction of CTGF in
primary osteoblasts [13]. Using Western Blot and RT-PCR
analysis, we found that Ets-1 protein levels (Figure 1A) and mRNA
levels (see Figure 1C) were induced by TGF-b1 treatment of
primary osteoblasts compared to treatment with TGF-b1 diluent
alone, and that this was concomitant with CCN2 induction
(Figure 1A). To determine if Ets-1 is required for CCN2 induction
by TGF-b1, two approaches were used. For the first approach, we
over-expressed Myc-tagged Ets-1 (Ets-1-Myc) and assessed CCN2
expression with or without TGF-b1 treatment (Figure 1B–C). For
these experiments, primary osteoblasts were transiently transfected
with either Ets-1-Myc or an empty (non-Ets-1 containing) vector.
Ets-1over-expression was confirmed by Western Blotting using an
anti-Myc antibody (Figure 1B). When we assessed CCN induction,
we found that expression of Ets-1 induced CCN2 expression
(Figure 1B), and that this expression was enhanced with both Ets-1
expression and TGF-b1 treatment. For the second approach, we
used Ets-1 siRNA to impair Ets-1 expression at the protein and
RNA level (Figure 1C). When we assessed CCN2 induction by
TGF-b1 treatment in cells where Ets-1 was impaired, we found a
significant reduction in CCN2 expression by TGF-b1 (Figure 1C),
demonstrating the requirement of Ets-1 for CCN2 induction by
TGF- b1 in osteoblasts.
CCN2 promoter activation by TGF-b1 requires Ets-1
In addition to CCN2 expression, we also assessed the
requirement of Ets-1 for CCN2 promoter activation by TGF-b1
in osteoblasts. For these studies, we transfected osteoblasts with our
previously characterized CCN2 promoter luciferase reporter [22]
and either over-expressed Ets-1 (Ets-1-Myc) or blocked Ets-1 using
Ets-1 specific siRNA (Figure 2). In Figure 2A, we found that Ets-1
over-expression alone induced CCN2 promoter activity at a level
similar to TGF-b1 treatment, and that this promoter activity is
significantly enhanced by simultaneous Ets-1 over-expression and
TGF-b1 treatment (Figure 2A), suggesting that Ets-1 and TGF-b1
synergistically activate the CCN2 promoter. When we blocked
Ets-1 with specific siRNA, we significantly impaired TGF-b1-
induced CCN2 promoter activation (Figure 2B). These results
demonstrate that Ets-1 is required for CCN2 protein induction
and promoter activation by TGF-b1, and that Ets-1 synergizes
with TGF-b1 to induce CCN2 in osteoblasts.
Ets-1 binding elements (EBE) mediate TGF-b1 induction
of the CCN2 promoter
Ets-1 regulates transcription of target genes in a tissue specific
manner by directly binding DNA at highly conserved GGA (A/T)
consensus sequences called Ets-1 binding motifs (EBE) [39,40,41].
Using bioinformatic analysis, we identified eight putative EBE sites
in the CCN2 proximal promoter (Figure 3A). In order to
determine the contributions of each of the EBE site, a site-
directed mutagenesis approach similar to that of Nakerakanti et al
was employed. [45]. Multiple promoter mutation constructs were
created that contained point mutations in the eight putative EBE
sites (Figure 3B) and cloned upstream into a pGL3 luciferase
reporter construct. Using a luciferase-based reporter approach
that we previously established in our laboratory [22], we found
that mutation of EBE sites #4-8 significantly impaired CCN2
promoter responsiveness to TGF-b1 (Figure 4) with sites #5, 6, 7,
and 8 having the greatest effect. In addition, we found that
mutation of EBE sites in closer proximity to either the TGF-b
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effect on CCN2 induction, suggesting potential synergetic
interaction of these EBE sites with the TRE, SBE, or both. In
order to determine if mutation of these sites prevented proteins
from osteoblast nuclear lysates from binding these mutated EBE
sites, electro-mobility shift assays (EMSA) were conducted using
probes harboring the mutated or wild type versions of EBE sites
#5-8 (Figure 5A). We found that nuclear proteins could bind the
EBE sites in a TGF-b1 inducible manner (data not shown), and
importantly that mutation of these EBE sites impaired normal
protein binding (see Figure 5B: lane 1 vs. 2; 3 vs. 4; 4 vs. 5, 6 and
7). Interestingly, mutation of specific EBE sites, such as EBE #7,
appeared to have a greater effect on protein binding affinity for
adjacent EBE sites (see effects on EBE #6 and #8, Figure 5: lane
6), suggesting that this site mediates protein complex formation on
adjacent EBE motifs. To validate that these sites were indeed bona
fide EBE sites and to specifically determine which complexes were
the result of Ets-1 protein binding, a super-shift EMSA approach
was utilized. For these studies, EMSAs were conducted, as
previously described, using the unmutated probes E-E-E (contain-
ing EBE #6-8) and S-E-T (containing EBE#5) (Figure 5A)
however in these reactions we included Ets-1 specific antibody. As
seen in Figure 6A, addition of the Ets-1 antibody to the E-E-E
probe reactions inhibited complex formation (indicated by black
arrow) in a dose-dependent manner (lane 4 [1 ul Ets-1 antibody]
vs. lane 5 [2 ul Ets-1 antibody]) compared to the no antibody lane
(lane 2) and the control antibody lane (lane 6), demonstrating that
Ets-1 binds the E-E-E probe. Importantly, this same weight band
also disappeared when we mutated the specific EBE sites
(Figure 5B), demonstrating that mutation of EBE sites prevents
Ets-1 binding at all three EBE motifs in this probe. We also
performed a super-shift EMSA using the S-E-T probe to test if Ets-
1 binds the EBE site found in this probe (Figure 6B). Addition of
the Ets-1 antibody to the S-E-T probe reactions also inhibited
complex formation (indicated by right grey arrows) in a dose-
dependent manner (lane 10 [1 ul Ets-1 antibody] vs. lane 11 [2 ul
Ets-1 antibody]) compared to the no-antibody lane (lane 8) and the
control antibody lane (lane 14), demonstrating that Ets-1 binds the
S-E-T probe. Additionally, since the S-E-T probe also contains a
SBE, we also tested if addition of Smad3 antibody inhibited
complex formation using this same approach and found that it
blocked similar bands as the Ets-1 antibody (see lanes 12 and 13)
when we used the S-E-T probe. Addition of Smad 3 antibody also
blocked several other complexes, demonstrating that Ets-1 and
Smad 3 synergize to form these protein complexes on EBE #5.
Discussion
Numerous studies have demonstrated that Ets-1 plays a role in
osteoblast differentiation and bone development [41,46,51]. Ets-1
is expressed in osteoblast and pre-osteoblast cells [41], and Ets-1
expression can be induced in the osteoblast cell line, MC3T3-E1,
and primary fetal rat calvaria cells by retinoic acid (RA), which is
known to exert profound effects on skeletal growth and
development, bone turnover, and induce specific cellular responses
in bone cells [41]. In addition, Ets-1 interacts with the osteoblast
transcription factor CbfA1 to regulate expression of the osteoblast
matrix gene osteopontin [46]. More recently, in a model for
distraction osteogenesis, Ets-1 was found to activate expression of
alkaline phosphatase, a marker for osteoblast differentiation [51].
However, while studies have demonstrated that Ets-1 is important
for osteoblast differentiation, its mechanism of action in these cells
Figure 1. Ets-1 is essential for TGF-b1 induction of CCN2 protein in osteoblasts. (A) Primary osteoblasts were cultured until they were 80%
confluent, serum deprived for 24 hrs and then treated with TGF-b1 (5 ng/ml) (+) or mock treated with TGF-b1 diluent (2). At 24 hrs post treatment,
cell lysates were harvested and assessed for CTGF and Ets-1 expression by Western blot analysis. (B) Primary osteoblasts were transfected with Ets-1-
Myc (+) or an empty vector (2) and then treated with TGF-b1 (5 ng/ml) (+) or mock treated with TGF-b1 diluent (2). At 24 hrs post treatment, cell
lysates were harvested and assessed for CCN2, Ets-1 and Myc expression by Western Blot analysis. (C) Primary osteoblasts were transfected with
100 nM of Ets-1 siRNA (Ets-1) or control siRNA (C) for 48 hrs. Following transfection, the cells were serum starved for 24 hrs and then treated with
5 ng/ml of TGF-b1( +) or TGF-b1 diluent (2) for 24 hrs. RNA was harvested and assessed for Ets-1 expression by RT-PCR. Cell lysates were harvested
and assessed for Ets-1 and CCN2 expression by Western Blot analysis. Each experiment is representative of at least three independent experiments.
doi:10.1371/journal.pone.0035258.g001
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osteoblast differentiation may in part be attributed to its
interaction with Cbfa1, identification of other downstream target
genes and elucidation of the precise role Ets-1 plays in osteoblast
differentiation remain an important area of investigation.
In this study we investigated the contributions of Ets-1 for
induction of CCN2 by TGF-b1 in primary, fetal rat calvarial
osteoblasts. CCN2 is emerging as an important factor in the
induction and control of osteogenesis. CCN2 is highly expressed in
active osteoblasts during osteogenesis [1], during fracture healing
[2,3], and in osteoblasts during bone formation and regeneration
[4]. Additionally, recombinant forms of CCN2 can elicit
osteoinductive responses in bone, enhance osteoblast differentia-
tion, and induce bone formation [2,5]. However, the signaling
mechanisms that control CCN2 expression, specifically in the
context of osteoblasts, are poorly understood. We have previously
identified two promoter motifs, the TGFb response element
(TRE/aka the BCE) and the SBE, that are both essential for
CCN2 promoter activation by TGF-b1 in osteoblasts [22,23]. In
addition, we have demonstrated that CCN2 protein induction
requires contributions of the Src, Smad, and Erk signaling
pathways, and that all of these pathways converge at the level of
the promoter, as Erk is necessary for both TRE and SBE
transactivation [22,23]. Several members of the Ets-1 family are
downstream signaling targets of the Ras-MAPK pathway [37],
and in certain cell types, Ets-1 is directly phosphorylated by Erk
and functions to transactivate downstream Erk responsive genes
[37,38,39,40]. Given the requirement of Erk signaling in the
context of CCN2 induction by TGF-b1 in osteoblasts, we
investigated the potential role of Ets-1 in CCN2 induction by
TGF-b1 in osteoblasts.
Ets-1 is known to be a downstream signaling effector for several
TGF-b1 responsive genes [42,43,44], and more recently Ets-1 has
been shown to function downstream of TGF-b1 for CTGF
induction in fibroblasts [45]. In this study, we demonstrated that
TGF-b1 treatment induces Ets-1 expression, and that this is
concomitant with induction of CCN2 in osteoblasts (Figure 1A).
Importantly, when we transiently over-expressed Myc-tagged Ets-
1 protein using a mammalian expression vector, we were able to
induce CCN2 expression (Figure 1B), and this was enhanced with
simultaneous Ets-1 over-expression and TGF-b1 treatment. To
confirm that Ets-1 was required for CCN2 induction by TGF-b1,
we used Ets-1 siRNA to impair Ets-1 expression (Figure 1C) and
found a significant reduction in CCN2 induction by TGF-b1
(Figure 1C), demonstrating the requirement of Ets-1 for CCN2
induction by TGF- b1 in osteoblasts.
In addition to CCN2 expression, we also assessed the
requirement of Ets-1 for CCN2 promoter activation by TGF-b1
in osteoblasts. When we over-expressed Ets-1 protein we found
that it induced CCN2 promoter activity at a level similar to TGF-
b1 treatment, and that this promoter activity was significantly
enhanced by simultaneous TGF-b1 treatment (Figure 2A),
suggesting that Ets-1 and TGF-b1 synergistically activate the
CCN2 promoter in osteoblasts. When we blocked Ets-1 with
specific Ets-1 siRNA, we significantly impaired TGF-b1 induced
CCN2 promoter activation (Figure 2B) further demonstrating that
Ets-1 is required for promoter activation by TGF-b1 in osteoblasts.
The Ets-1 DNA binding domain (ETS) consists of 85 amino
acids which recognize a highly conserved consensus sequence,
GGA(A/T), called an Ets-1 binding motif (EBE) [39,40,41]. Using
bioinformatic analysis, we identified eight putative EBE sites in the
CCN2 proximal promoter in various degrees of proximity to the
TRE and SBE (Figure 3). EBE sites #1-4 are novel and have
never previously been described, while EBE sites # 5-8 have been
identified by other groups [45,48], but are novel in our system as
their contribution to CCN2 induction by TGF-b1 in osteoblasts
has not been described. In order to determine the relative
contributions of these motifs to CCN2 induction by TGF-b1, we
employed a site-directed mutagenesis approach (Figure 3B) and
found that mutation of EBE sites #4-8 significantly impaired
CCN2 promoter responsiveness to TGF-b1 (Figure 4), with sites
#5-8 having the greatest effect. Interestingly, mutation of EBE
sites in closer proximity to either the TRE or SBE had a more
dramatic effect on CCN2 promoter activation by TGF-b1,
suggesting potential synergetic interaction of these EBE sites with
the TRE, SBE, or both. These results are consistent with a
previous study in fibroblasts [45], where mutation of EBE sites #5
and #6 significantly impaired TGF-b1 induction of CCN2,
however in that study, in contrast to what we found in osteoblasts,
mutation of EBE sites #7 and #8 had no effect on CCN2
induction by TGF-b1, demonstrating that specific EBE sites
Figure 2. Ets-1 synergizes with TGF-b1 for CCN2 promoter
induction in osteoblasts. (A) Osteoblasts were plated in 96 well
tissue culture plates and transfected with either 0.4 mg of an empty
vector control (2) or the Ets-1 expression construct (+). All samples
were co-transfected with 0.4 mg of our previously described CCN2
promoter luciferase reporter [22] and 0.2 mg of a renilla luciferase
expression vector as an internal control. The cells were serum starved
for 24 hrs and then treated with TGF-b1 (5 ng/ml) (+) or mock treated
(2) with TGF-b1 diluent for 24 hrs. Luciferase activity was then assessed
and expressed as a ratio of firefly/renilla luciferase (+SEM, n=6).
A=p,0.05 compared to +TGF-b1 only or +Ets-1 only. (B) Osteoblasts
were plated in 96 well tissue culture plates and transfected with either
100 nM of Ets-1 siRNA (Ets-1) or control siRNA (C) for 48 hrs. All samples
were co-transfected with 0.4 mg of our previously described CCN2
promoter luciferase reporter [22] and 0.2 mg of a renilla luciferase
expression vector as an internal control. The cells were serum starved
for 24 hrs and then treated with 5 ng/ml of TGF-b1( +) or mock treated
(2) with TGF-b1 diluent for 24 hrs. Luciferase activity was then assessed
and expressed as a ratio of firefly/renilla luciferase (+SEM, n=6). Star
symbol indicates p,0.05 compared to control siRNA.
doi:10.1371/journal.pone.0035258.g002
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in a cell type specific manner.
When we tested if mutation of these specific sites (#5-8)
prevented protein binding, we found that nuclear proteins could
bind each EBE site in a TGF-b1 inducible manner (data not
shown), and importantly that mutation impaired protein binding
(Figure 5). Interestingly, mutation of specific EBE sites, such as
EBE #7, appeared to have a greater effect on protein binding
affinity for adjacent EBE sites (see effects on EBE #6 and #8,
Figure 5: lane 6), suggesting that this site mediates protein complex
formation on adjacent EBE motifs. Previous studies in other cell
systems have demonstrated a similar correlation between binding
affinity and EBE spacing, where EBE motifs in closer proximity to
one another have a higher affinity for Ets proteins then when
motifs are spaced farther apart [52]. In addition, it is also known
that the nucleotide sequences flanking these EBE motifs can
influence the binding of particular Ets proteins [53,54], and that
Ets-1 protein can also bind to single or dual EBE motifs, with
binding to multiple motifs considered more stable [55]. Our results
clearly show that EBE #7 appears to be a critical site for protein
complex formation, and that this protein complex formation is the
result of Ets-1 binding (Figure 6A); however, how it coordinates/
stabilizes protein complex formation and the identities of all the
proteins involved in these complexes is an important area of
investigation for future studies.
Figure 3. Identification of putative Ets-1 sites in the CCN2 promoter. (A) The CCN2 proximal promoter (pictured are bases 2293 to +1)
contains eight putative Ets-1 binding sites (EBE 1–8) (open boxes), and these sites are in close proximity to the TRE (grey box) and SBE (black box). (B)
Multiple mutation constructs were created containing individual substitutions of the EBE at positions 1–8 (DEBE 1–8) in the CCN2 proximal promoter
that was cloned into a pGL3-firefly luciferase reporter construct.
doi:10.1371/journal.pone.0035258.g003
Figure 4. EBE sites are required for CCN2 promoter activation
by TGF-b1 in osteoblasts. Osteoblasts were plated in 96-well tissue
culture plates and transfected with 0.4 mg of either EBE mutation
construct 1–8, pGL3-Basic (negative control) or W787 (positive control)
and all were co-transfected with 0.2 mg of a renilla luciferase expression
vector (internal control) for 24 hrs. The cells were serum starved for
24 hrs and then treated with TGF-b1 (5 ng/ml) for 24 hrs. Luciferase
activity was assessed, and expressed as a % of activity obtained using
the full length W787 construct. (+SEM, n=6). A=p,0.05 compared to
W787.
doi:10.1371/journal.pone.0035258.g004
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binding sites and to specifically determine which complexes
resulted from Ets-1 protein binding, a super-shift EMSA approach
using Ets-1 antibody was employed. We tested Est-1 binding on
EBE sites #6-8 found on the E-E-E probe (Figure 6A) and Ets-1
binding on EBE site #5 found on the S-E-T probe (Figure 6B).
We found that we could block protein complex formation on all
EBE sites using Ets-1 antibody, demonstrating that Ets-1 binds at
these sites; moreover, we were also able to block the same weight
band that disappeared when we mutated the specific EBE sites
(Figure 5B), demonstrating that mutation of EBE sites prevents
Ets-1 binding at all four EBE motifs in these probes. Transcrip-
tional activation by Ets-1 protein can function in a combinatorial
manner through association with other transcription co-factors to
transactivate target genes [39,40,46,47]. Recently, Ets-1 was found
to synergize with Smad 3 to activate CTGF expression in
fibroblasts [48], and we recently demonstrated the requirement of
Smad 3 for CCN2 induction by TGF-b1 in osteoblasts [22]. In
order to determine if Smad 3 played a role in Ets-1 biding in
osteoblasts, we also conducted super-shift experiments using our S-
E-T probe (EBE #5) and Smad 3 antibody. Interestingly, addition
of Smad 3 antibody also blocked similar bands as the Ets-1
antibody (Figure 6B) in these experiments, suggesting that Ets-1
and Smad 3 synergize to form these protein complexes at EBE #5.
Whether Smads and Ets-1 bind prior to CCN2 promoter binding
or whether this interaction is secondary to complex formation on
the promoter is unknown. Additionally, the role of Smads on Ets-1
binding of other EBE sites including EBE #6-8 is unknown, and
studies addressing these interactions are warranted in the future.
In conclusion, this study demonstrates that Ets-1 is an essential
downstream signaling component for CCN2 induction by TGF-b1
in osteoblasts, and that specific EBE sites in the CCN2 promoter
are required for CCN2 promoter transactivation in osteoblasts.
This is the first study that has explored the contributions of Ets-1
for TGF-b1 induction of CCN2 in osteoblasts. Identification of
CCN2 as a downstream target of Ets-1 reveals a potential
mechanism that may help unravel some of the effects of Ets-1 on
osteoblast growth and differentiation. In addition, we have
identified novel EBE sites in the CCN2 proximal promoter that
are required for CCN2 induction by TGF-b1 in osteobalsts and
have demonstrated that these EBE sites cooperate to achieve
protein binding. We have also found that Ets-1 and Smad 3
synergize to achieve protein binding in EBE sites in close
proximity to the SBE. Future studies will be necessary to assess
the role that these EBE motifs play on SBE and TRE occupancy
and the potential interaction of other nuclear co-factors like
Smads, p300 and CBP on EBE transactivation in osteoblasts.
Materials and Methods
Ethics Statement
No human subjects were used in this study. This study was
approved by the IACUC review board of the University of
Scranton, Scranton PA. (IACUC approval #13-07). All animals
were handled according to national and international guidelines
following the principles in the NIH Guide for the Care and Use of
Laboratory Animals (U.S. Department of Health and Human
Services, Publ. No. 86-23, 1985) and in accordance with principles
established in the Weatherall report.
Reagents
Transforming Growth Factor-b1 (TGF-b1) was purchased from
Calbiochem and reconstituted as 1 mg/ml in 4 mM HCl with
0.1% bovine serum albumin. Anti-actin antibody was purchased
from Sigma. Anti-CTGF and anti-ETS-1 antibodies were
purchased from Santa Cruz. Horseradish peroxidase conjugated
anti-rabbit and anti-mouse IgG antibodies were obtained from
Pierce. Myc-DDK-Tagged Ets-1 expression vector was purchased
from OriGene.
Source of Animals
Primary osteoblasts were derived from bone (calvaria) of
neonatal Sprague Dawley rats purchased from Charles River.
All animals were handled according to the principles in the NIH
Guide for the Care and Use of Laboratory Animals (U.S.
Department of Health and Human Services, Publ. No. 86-23,
1985) and guidelines established by the IACUC of the University
of Scranton (Scranton, PA).
Primary Osteoblast Cell Culture
Primary osteoblast cultures were obtained using neonatal rats as
previously described [2,5,13]. Primary cells were isolated from
parietal calvaria from which the periosteum and cranial sutures
were removed to reduce non-osteoblast cell contamination.
Figure 5. Mutation of EBE sites prevents protein complex
binding. (A) Electro-mobility shift assays (EMSA) probes were created
that were homologues to the CCN2 promoter and contained either
mutated or unmutated EBE sites (#5-8) as indicated. Each probe was
dsDNA and 59 biotinylated. (B) Electro-mobility shift assays (EMSA) from
nuclear lysates were generated from osteoblasts that were treated with
TGF-b1 (5 ng/ml) for 2 hrs. Nuclear protein binding to the wild type and
mutated EBE sites in the CTGF promoter was assessed using 5 mgo f
nuclear lysates. The lane number above each well corresponds to the
probe used for that reaction. The experiment was repeated four times
with similar results.
doi:10.1371/journal.pone.0035258.g005
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15, 25, and 25 min at 37uC in a shaking water bath with 0.1%
collagenase-P (Roche)/0.25% trypsin (Mediatec). The first two
digestions are performed to remove non-osteoblast cells and are
discarded. Osteoblast-enriched cell populations were obtained
from the 3
rd–5
th digestions of the calvarial pieces. These cells were
plated in 100 mm dishes (Falcon) at 5610
5 cells/plate in
osteogenic media consisting of Earle’s Minimal Essential Medium
(EMEM; Mediatec) supplemented with 10% fetal calf serum (FCS;
Mediatec), 50 mg/ml ascorbic acid (Sigma) and 10 mM b-
glycerophosphate (Sigma). The cells were incubated at 37uC with
5% CO2 with a change of media every three days until they
reached 80% confluence. Cells were sub-cultured under identical
conditions for utilization in experiments following the third
passage. We have previously shown that these culture conditions
result in an enhanced (.90%) population of cells committed to the
osteoblast lineage using specific markers of osteoblast differentia-
tion (e.g. Runx2, Osterix) [2,13].
Promoter Constructs
The previously characterized pGL3-W787 vector [22] was used
to construct multiple mutation constructs using previously defined
mutations [45] for each identified EBE site. Point mutations were
introduced using QuickChange Site directed mutagenesis kit
(Stratagene) the following primers (IDT): EBE -1: 59 CATCCAA-
GAGACTACAGTCCCATGAATTAAAAAAAATCTAAAAC-
AGTGAAAAAGA -39,5 9- TCTTTTTCACTGTTTTAGATT-
TTTTTTAATTCATGGGACTGTAGTCTCTTGGATG -39;
EBE 0: 59- GAACTGGTAAAGCGATTTTTAAGAAGTTAA-
GATTCGAGAAATAATCCTTGTTCA -39,5 9- TGAACAAG-
GATTATTTCTCGAATCTTAACTTCTTAAAAATCGCTT-
TACCAGTTC -39; EBE 1: 59- TCATGTATTTCTAAGTT-
ATATTTCATCATTAAGGGTGCGAAGAGGATACAG -39,
59- CTGTATCCTCTTCGCACCCTTAATGATGAAATATA-
ACTTAGAAATACATGA -39; EBE 2: 59- GCTGGAAACA-
CAACGCCTTTTTTTTTCTTAATGGCCAGCTAAAGTG -
39,5 9- CACTTTAGCTGGCCATTAAGAAAAAAAAAGGCG-
TTGTGTTTCCAGC -39; EBE 3: 59- GCCAGCTTTTTCA-
GACGGATTAATGTGGAGTGTCAAGGGG -39,5 9- CCCC-
TTGACACTCCACATTAATCCGTCTGAAAAAGCTGGC -
39; EBE 4: 59- GTGTGAGTTGATGAGGCATTAAGGTGGG-
GAGGAATGCG -39,5 9- CGCATTCCTCCCCACCTTAATG-
CCTCATCAACTCACAC -39; EBE 5: 59- GGCAGGAAGG-
TGGGGATTAATGCGAGGAATGTCC -39,5 9- GGACATTC-
CTCGCATTAATCCCCACCTTCCTGCC -39; EBE 6: 59- AA-
GGTGGGGAGGAATGCGATTAATGTCCCTGTTTGTGT-
AG -39,5 9- CTACACAAACAGGGACATTAATCGCATTC-
CTCCCCACCTT -39. Mutations were confirmed with sequenc-
ing in both directions (Genewiz).
Figure 6. Ets-1 binds to EBE sites in the CCN2 promoter in osteoblasts. Electro-mobility shift assays (EMSA) from nuclear lysates were
generated from osteoblasts that were treated with TGF-b1 (5 ng/ml) for 2 hrs. (A) Nuclear protein binding to the wild type E-E-E (lanes 1–6) (this
probe contains EBE # 6-8; for probe design see Figure 6) probe was assessed using 5 mg of nuclear lysates for each reaction. In some reactions, Ets-1
antibody was added at increasing concentrations (1 ug of antibody in lane 4; Two micrograms of antibody in lane 5) to test for Ets-1/probe
interaction. Control antibody (2 ug) was also used (lane 6; C). In some cases, probe only (lane 1) or a molar excess of unlabeled probe (lane 3) was also
used to demonstrate specificity. (B) Nuclear protein binding to the wild type S-E-T (lanes 7–14) (this probe contains EBE#5; for probe design see
Figure 6) probe was assessed using 5 mg of nuclear lysates for each reaction. In some reactions, Ets-1 antibody was added at increasing
concentrations (1 ug of antibody in lane 10; 2 ug of antibody in lane 11) to test for Ets-1 protein/probe interaction or Smad 3 antibody (1 ug of
antibody in lane 12; 2 ug of antibody in lane 13) to test for Smad 3 protein/probe interaction. Control antibody (2 ug) was also used (lane 14). In
some cases, probe only (lane 7) or a molar excess of unlabeled probe (lane 9) was also used to demonstrate specificity.
doi:10.1371/journal.pone.0035258.g006
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2610
6 cells/100 mm culture dish were washed twice in PBS
and harvested from culture dishes with RIPA buffer (Pierce)
according to the manufacturer’s instructions. The whole cell
lysates were stored at 220uC for later Western blot studies.
Nuclear lysates were obtained using the NE-PER Nuclear Protein
Extraction Kit (Pierce) as per the manufacturer’s instructions.
Total protein concentrations were measured using the BCA
Protein Assay Reagent Kit (Pierce) according to the manufactur-
er’s instructions. Twenty mg of protein from each sample were
mixed with 16NuPAGE LDS Sample Buffer and 16NuPAGE
Sample Reducing Agent (Invitrogen) and heated at 95uC for
7 minutes. Samples were subjected to electrophoresis on NuPAGE
10% Bis-Tris gels (Invitrogen) and transferred to Hybond ECL
membranes (GE Healthcare) by electroblotting. After 1 hour
blocking in 5% BSA or 3% dry milk/0.5% BSA (per antibody
instructions) at room temperature, blots were incubated with one
of the following primary antibodies: Ets-1 (1:200), actin (1:5000),
and CTGF (1:200), and then with the corresponding HRP-
conjugated secondary antibody (1:20,000). Antigens were detected
using the Pierce Supersignal West Pico Chemiluminescent
Substrate System.
Electro-Mobility Shift Assay
Nuclear extracts from TGF-b1-treated cells were prepared
following the nuclear protein separation protocol described above.
The electro-mobility shift assays and used in this study were
performed as previously described [22]. Biotinylated oligonucle-
tide probes were purchased from Integrated DNA Technologies.
The binding reaction was composed of 5 mg of nuclear extract,
60 fmol of labeled probe, and binding buffer (20 mM Tris
(pH8.0), 0.5 mM EDTA, 10% glycerol and 1 mM DTT). After
incubating at RT for 30 min the entire sample was loaded on a
NuPAGE 7% Tris-Acetate gel (Invitrogen), subjected to electro-
phoresis in native tris-glycine running buffer, and transferred to
Biodyne B Pre-Cut Modified Nylon Membranes (Thermo) by
electroblotting. Shifts of the biotinylated probes were detected
using the Chemiluminescent Nucleic Acid Detection Module
(Thermo).
Luciferase Assays
Luciferase activity was determined using the Dual-Glo luciferase
assay (Promega) according to the manufacturer’s instructions.
Primary osteoblasts were plated in a 96-well microplate (2.4610
4
cells/well), transfected with 0.4 mg of the unmutated pGL3-W787
reporter vector or one of the eight EBE mutant vectors, and co-
transfected with 0.2 mg of a Renilla (internal control) luciferase
vector. Following transfection, the cells were serum starved
overnight and treated with TGF-b1 (5 ng/ml) for an additional
24 hours. Luciferase activity was measured using a SpectraMax
M5 Microplate Reader. Relative luciferase activity was expressed
as a ratio of firefly/renilla luminescence values. All samples were
normalized to an untreated (cells only) or mock treated (empty
vector or diluent only) control reaction.
RT-PCR
RT-PCR was performed as previously described [56]. Briefly,
RNA was extracted from primary osteoblasts that were transfected
with 100 nM of Ets-1 siRNA or control siRNA (control) for
48 hrs. Following transfection with siRNA, the cells were serum
starved for 24 hrs and then treated with 5 ng/ml of TGF-b1 for
24 hrs. Total RNA was harvested using Trizol (Invitrogen)
according to the manufacturers directions. First strand synthesis
was performed using SuperScript III (Invitrogen) according to the
manufacturers directions and amplified using previously described
primers and conditions for Ets-1 and GAPDH [56].
Data Analysis
For all quantitative data, analysis of variance (ANOVA) was
employed to evaluate the effect of one variable on two or more
independent groups. In the event of a significant group effect,
individual pairs of means were compared using the Bonferroni
post-hoc test. Data were calculated as mean+SEM, and in some
cases, converted to percent of control. A value of p,0.05 was used
to determine whether differences were statistically significant.
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